“Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records” (2019) SKIN The Journal of Cutaneous Medicine, 3(2), p. 173. doi:10.25251/skin.3.2.13.